|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 142.50 GBX | 0.00% |
|
+0.71% | +11.33% |
| 06-02 | Diaceutics PLC, 2025 Earnings Call, May 26, 2026 | |
| 05-26 | Diaceutics PLC Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: Diaceutics PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 112.2 | 85.75 | 63.68 | 73.32 | 106.1 | 120.7 | 120.7 | - |
| Change | - | -23.6% | -25.74% | 15.14% | 44.67% | 13.75% | 0% | - |
| Enterprise Value (EV) 1 | 87.1 | 66.08 | 43.84 | 56.65 | 93.32 | 101.3 | 112.9 | 108.5 |
| Change | - | -24.13% | -33.66% | 29.24% | 64.73% | 8.6% | 1.55% | -3.92% |
| P/E Ratio | 393x | - | 89.9x | -42x | -62.1x | - | - | - |
| PBR | - | - | 1.53x | 1.8x | 2.66x | 2.67x | 2.94x | 2.62x |
| PEG | - | - | - | 0x | 25.71x | - | - | - |
| Capitalization / Revenue | 8.84x | 6.15x | 3.26x | 3.09x | 3.3x | 2.83x | 2.57x | 2.14x |
| EV / Revenue | 6.86x | 4.74x | 2.25x | 2.39x | 2.9x | 2.64x | 2.4x | 1.93x |
| EV / EBITDA | 162x | 28.1x | 12.2x | 24x | 22.2x | 13.4x | 10.9x | 7.88x |
| EV / EBIT | -132x | 120x | 76.4x | -18.8x | -38x | 57.5x | 35.3x | 21.1x |
| EV / FCF | - | -13.1x | 194x | -16x | -23.4x | -19.2x | 228x | 15.9x |
| FCF Yield | - | -7.61% | 0.52% | -6.26% | -4.27% | -5.2% | 0.44% | 6.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.0034 | - | 0.0084 | -0.0207 | -0.0202 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 12.7 | 13.94 | 19.5 | 23.7 | 32.16 | 38.44 | 47 | 56.31 |
| EBITDA 1 | 0.539 | 2.349 | 3.583 | 2.357 | 4.206 | 7.573 | 10.35 | 13.77 |
| EBIT 1 | -0.658 | 0.55 | 0.574 | -3.018 | -2.455 | 1.761 | 3.2 | 5.149 |
| Net income 1 | 0.263 | 0.561 | 0.724 | -1.746 | -1.703 | 0.097 | -1.1 | 1.5 |
| Net Debt 1 | -25.14 | -19.68 | -19.84 | -16.67 | -12.74 | -7.344 | -7.71 | -12.14 |
| Reference price 2 | 1.335 | 1.020 | 0.755 | 0.870 | 1.255 | 1.425 | 1.425 | 1.425 |
| Nbr of stocks (in thousands) | 84,069 | 84,069 | 84,339 | 84,274 | 84,515 | 84,670 | 84,670 | - |
| Announcement Date | 3/15/21 A | 3/22/22 A | 4/17/23 A | 5/21/24 A | 5/13/25 A | 5/26/26 A | - | - |
1GBP in Million2GBP
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 2.89x | 14.99x | -.--% | 162M | |
| -143.14x | 21.82x | 52.41x | -.--% | 59.49B | |
| 35.29x | 2.7x | 21.36x | 1.25% | 3.94B | |
| 103.75x | 13.01x | 18.96x | 0.3% | 3.28B | |
| -26.56x | - | - | 0.1% | 1.3B | |
| 40.97x | 16.9x | 26.22x | 0.56% | 1.22B | |
| 15.24x | - | - | 0.38% | 1.13B | |
| 23.42x | 3.68x | 13.25x | 0.7% | 1.07B | |
| Average | 7.00x | 10.17x | 24.53x | 0.41% | 8.95B | |
| Weighted average by Cap. | -111.69x | 19.90x | 47.90x | 0.11% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXRX Stock
- Valuation Diaceutics PLC
Select your edition
All financial news and data tailored to specific country editions
